CD274 and non-small cell lung carcinoma: In a phase III clinical trial of Durvalumab (anti-PD-L1) after chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC), the median progression-free survival (PFS) was 16.8 (13.0-18.1) months in the Durvalumab group (10 mg/kg, every two weeks), compared with 5.6 (4.6-7.8) months in the placebo group, demonstrating the survival benefit of anti-PD-L1 therapy in NSCLC [9].